|
|
The Clinical Implications of the Efficacy and Safety in Older Patients with mCRPC Receiving Cabazitaxel vs Abiraterone or Enzalutamide - The CARD Trial
|
Stephen J. Freedland, MD and William Oh, MD
Stephen Freedland and William Oh join Alicia Morgans to discuss the efficacy and safety in older patients with mCRPC receiving cabazitaxel vs abi or enza, an analysis of the CARD Trial.
|
|
|
|
|
|
|
|
|
Novel Radiopharmaceuticals In Development For Treatment in Advanced Prostate Cancer |
Michael J. Morris, MD
Michael Morris joins Alicia Morgans to discuss the new agents in development in the field of radiopharmaceuticals in advanced prostate cancer. |
|
|
|
|
|
|
|
|
In Pursuit of Patient-Centered Care |
Karen Knudsen, Ph.D.
Karen Knudsen joins Alicia Morgans to discuss the motivation, vision, and drivers behind this year's GU ASCO 2020 meeting "in pursuit of patient-centered care". |
|
|
|
|
|
|
|
|
IMbassador250: A Study of Atezolizumab in Combination with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Christopher Sweeney, MBBS |
Alicia Morgans and Christopher Sweeney discuss the IMbassador250 trial results presented at the AACR 2020 virtual meeting. Dr. Morgans and Dr. Sweeney discuss the use of biomarkers and the development of effective treatment plans for metastatic prostate cancer patients. |
|
|
|
|
|
|
|
|
|
|
EDITOR SELECTED ABSTRACTS AND COMMENTARIES |
|
|
|
|
Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone |
Bertrand F. Tombal, MD, PhD |
Bertrand F. Tombal and co-authors present analyses aimed at evaluating the robustness of the survival benefit observed in the CARD study by (1) utilizing a multivariable Cox proportional hazards model to assess the impact of baseline prognostic factors on survival and (2) evaluating overall survival from various treatment time points in each treatment arm. |
|
|
|
|
|
|
|
|
TheraP: A Randomized Phase II Trial of 177Lu-PSMA-617 Theranostic Versus Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Progressing after Docetaxel: Initial Results (ANZUP protocol 1603)
|
Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
|
At the 2020 ASCO Annual Meeting Virtual Scientific Program, Michael Hofman presented on the first randomized study that evaluates 177Lu-PSMA-617 vs cabazitaxel for men with mCRPC after docetaxel. |
|
|
|
|
Treatment of Chemotherapy-Naïve mCRPC Using Abiraterone Acetate with or without Cabazitaxel |
Susan Slovin, MD, Ph.D. |
Presenting during the Prostate Cancer Session at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium, Dr. Slovin and colleagues shared the results of this trial. This is a multicenter non-comparative randomized Phase II trial in which patients were randomized 1:1 to abiraterone + prednisone with crossover to cabazitaxel upon abiraterone + prednisone failure, or the combination of abiraterone + prednisone + cabazitaxel. |
|
|
|
|
|